The function of myeloid-derived suppressor cells in COVID-19 lymphopenia.
Int Immunopharmacol
; 112: 109277, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2041839
ABSTRACT
Coronavirus disease 2019 (COVID-19) has caused a global pandemic and presents a significant danger to public health. Lymphopenia is considered to be the defining characteristic of severe COVID-19, especially in elderly people. Lymphopenia has been suggested as a pivotal factor in disease severity. To minimize mortality in COVID-19 patients, it is essential to have a deeper understanding of the processes behind lymphocytopenia. Recently, myeloid-derived suppressor cells (MDSCs) have been confirmed as a key mediator of lymphopenia. MDSCs are characterized by their powerful capacity to suppress T cells and eventually contribute to the course of illness. Targeting these cells may improve the disease prognosis. In this article, we analyze the available research on MDSCs in lymphopenia and discuss their immunopathologic changes and prospective therapeutic targets in patients with COVID-19 lymphocytopenia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Myeloid-Derived Suppressor Cells
/
COVID-19
/
Lymphopenia
Type of study:
Observational study
/
Prognostic study
Limits:
Aged
/
Humans
Language:
English
Journal:
Int Immunopharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
Year:
2022
Document Type:
Article
Affiliation country:
J.intimp.2022.109277
Similar
MEDLINE
...
LILACS
LIS